Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
SB-715992 · 2 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| Subjects receiving carboplatin and SB-715992 | EXPERIMENTAL | Subjects will receive carboplatin on Day 1 as an intravenous (IV) infusion over 30 minutes followed by 1-hour IV infusion of SB-715992 once every 21 days. |
| Name | Type | Description |
|---|---|---|
| SB-715992 | DRUG | SB-715992 will be available either as 5 milliliter (mL) vial containing 4 milligram (mg) of SB-715992 or 4 mL vial containing 5 mg of SB-715992 at a concentration of 1 mg/mL OR a 10 mL vial that contains 10 mg of SB-715992 in a 10 mL solution at a concentration of 1 mg/mL. |
| carboplatin | DRUG | Carboplatin will be available as sterile, lyophilized white powder available in single-dose vials containing 50 mg, 150 mg, and 450 mg of carboplatin for administration by IV infusion. Each vial will be reconstituted with either Sterile Water for Injection, USP, 5% Dextrose in Water (D 5 W), or 0.9% Sodium Chloride Injection, USP. |
| docetaxel | DRUG | - |
Inclusion criteria: * Histologically or cytologically confirmed diagnosis of an advanced solid tumor malignancy that is not responsive to standard therapies or for which there is no standard therapy. * ECOG (Eastern Cooperative Oncology Group) Performance Status of 0-2. Exclusion criteria: * Fema...
SB-715992 is an investigational small molecule being studied for the treatment of solid tumors and solid tumor cancer. It is in Phase 1 clinical development, meaning it has not yet been approved by regulatory authorities and remains under investigation for safety and efficacy in patients.
SB-715992 is being developed by GSK plc, a pharmaceutical company listed on the stock exchange under the ticker symbol GSK. The drug is currently in Phase 1 clinical trials for oncology indications.
SB-715992 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still being studied in clinical trials for safety and efficacy in patients with solid tumors.
SB-715992 has been studied in two completed Phase 1 clinical trials. One trial, NCT00136578, evaluated ispinesib in combination with carboplatin in patients with solid tumors. Another trial, NCT00169520, studied SB-715992 in combination with docetaxel in patients with solid tumor cancer.
Yes, SB-715992 is also known as ispinesib. Clinical trial NCT00136578, which evaluated ispinesib in combination with carboplatin in patients with solid tumors, is a study of SB-715992.